Ryoo Byung-Hwan – CEO, Yungjin – South Korea
The CEO of Yungjin, a leading Korean pharma company, talks about the revitalization of the company he has overseen since being appointed in 2010. To begin, could you please…
Yungjin Pharm. Co., Ltd was established in 1952, has been playing a major role as a forerunner in the Korean pharmaceutical industry for half a century. With the corporate mission of “To relieve the suffering of mankind from diseases with our innovative, effective and safe pharmaceutical products”, Yungjin has contributed to human health not only within Korea, but also through global expansion. As a result, Yungjin has received a total of 25 awards including the President’s Award for Superior Product Development, the Prime Minister’s Award, several Industry Awards, and many more. These accomplishments demonstrate Yungjin’s sustainability and commitment to the development of innovative products and business excellence in both overseas and domestic segments.
Contact Details:
451-20, Cheonho-dong,
Gangdong-gu,
Seoul, Korea
Tel : 82 2 2041 8200
Fax : 82 2 4630 9544
The CEO of Yungjin, a leading Korean pharma company, talks about the revitalization of the company he has overseen since being appointed in 2010. To begin, could you please…
South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way.…
After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge…
Stephen Yoo highlights the pioneering work that STCube Pharmaceuticals – a US subsidiary of Korean firm STCube – is undertaking in the immuno-oncology field, its three technology platforms, partnership approach,…
Founder and CEO of GeneMedicine, Dr Chae-Ok Yun, explains how the company, specialised in oncolytic virus development, has progressed since we last interviewed her two years ago, with one of…
Eutilex’s CEO, Byoung S. Kwon, outlines the company’s approach to cancer research, including its antibodies and CAR-T-centred pipeline and focus on unmet needs. He also explains recent partnerships in China.…
The latest healthcare and pharma news from South Korea, including SK Bioscience’s COVID-19 vaccine, Daewoong’s partnership with AstraZeneca Korea and UCI Therapeutics, Vivozon production halt and GC’s acquistion of US-based…
Chair & Founder, Regenerative Medicine Acceleration Foundation (RMAF), So Ra Park MD, PhD*, comments on the regenerative medicine ecosystem in Korea, the country’s new legislative approach to the field, and…
KHIDI’s Soonman KWON outlines the public health R&D funding landscape in Korea, plans to increase Korea’s capacity to develop and produce its own vaccines in the wake of the COVID-19…
Two decades ago, South Korean company Celltrion embarked on a quest to find the necessary resources to produce biopharmaceuticals. It took five years for their manufacturing plant to receive GMP…
Boasting a pharma market size of KRW 23.2 trillion (USD 19.2 billion) for 2020, South Korea is one of Asia’s leading pharma nations. Read on for a ranking of the…
Amid global supply shortages and shipment delays for COVID-19 vaccines, South Korea has launched an ambitious 2.2 trillion won (USD 1.9 billion) investment plan to become one of the world’s…
Francis Van Parys, vice president commercial Asia-Pacific at Cytiva, a global life sciences leader dedicated to advancing and accelerating therapeutics, highlights the firm’s tireless work to meet the exponential demand…
See our Cookie Privacy Policy Here
